Meropenem Injection

[06 April 2016]

Products Affected - Description

All presentations are currently available

Reason for the Shortage

  • BBraun had meropenem on shortage due to increased demand.
  • Fresenius Kabi states the reason for the shortage was increased demand.
  • Hospira has meropenem available.
  • Sandoz discontinued meropenem injection in January 2015.
  • AstraZeneca had Merrem on shortage due to increase demand.

Available Products

Merrem injection, AstraZeneca
1 gram, vial, 10 count (NDC 00310-0321-30)
500 mg, vial, 10 count (NDC 00310-0325-20)
Meropenem injection, BBraun
1 gm/50 mL, premixed bag, 24 count (NDC 00264-3185-11)
500 mg/50 mL, premixed bag, 24 count (NDC 00264-3183-11)
Meropenem injection, Fresenius Kabi
1 gram, vial, 10 count (NDC 63323-0508-30)
500 mg, vial, 10 count (NDC 63323-0507-20)
Meropenem injection, Hospira
1 gram, vial, 25 count (NDC 00409-3506-01)
500 mg, vial, 25 count (NDC 00409-3505-01)

Estimated Resupply Dates

All marketed presentations are available.

Related Shortages


April 6, March 3, February 22, 10 and 3, January 13 and 6, 2016; December 1, November 18 and 11, October 13, September 30 and 1, August 6, 2015, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
ASHP Product Listing